Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis

Journal of Clinical Pharmacology

Volumn 46, Issue 10, 2006, Pages 1128-1138

  Mistry, Goutam C ^a,b   Majumdar, Anup K ^a   Swan, Suzanne ^b   Sica, Domenic ^c   Fisher, Alison ^a   Xu, Yang ^a   Hesney, Michael ^a   Xi, Liwen ^a   Wagner, John A ^a   Deutsch, Paul J ^a  

^a Department of Clinical Pharmacology ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ertapenem; Pharmacokinetics; Renal insufficiency

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ERTAPENEM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HUMAN; INFUSION; KIDNEY FAILURE; MALE; SIDE EFFECT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BETA-LACTAMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY; TIME FACTORS;

EID: 33748675494     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006291839     Document Type: Article

References (17)

1. Gill CJ, Jackson JJ, Gerckens LS, et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-0826 (L-749345). Antimicrob Agents Chemother. 1998;42:1996-2001.
2. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem vs piperacillin/tazobactam in the treatment of complicated intraabdominal infection: results of a double blind, randomized comparative phase III trial. Ann Surg. 2003;237:235-245.
3. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times a day for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460-1468.
4. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, et al. A study to evaluate the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002;34:1076-1083.
5. Vetter N, Cambronero-Hernandez E, Rohlf J, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for treatment of hospitalized adults with community-acquired pneumonia. Clin Ther. 2002;24:1770-1785.
6. Tomera KM, Burdmann EA, Pamo Reyna OG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46:2895-3000.
7. Roy S, Higareda I, Angel-Muller E, et al. Results of a phase III randomized, double-blind study of ertapenem (ETP) vs piperacillin/azobactam (P/T) for acute pelvic infection (Inf) in women: 41st Intersci Conf [abstract]. Antimicrob Agents Chemother. 2001; abstract L-888.
8. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother. 1997;41:1830-1831.
9. Sundelof JG, Hajdu R, Gill CJ, Thompson R, Rosen H, Kropp H. Pharmacokinetics of L-749345, a long-acting carbapenem antibiotic, in primates. Antimicrob Agents Chemother. 1997;41:1743-1748.
10. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother. 2002;46:3506-3511.
11. INVANZ (ertapenem sodium) [product circular]. Whitehouse Station, NJ: Merck & Co Inc; 2001.
12. Musson DG, Birk KL, Cairns AM, et al. High performance liquid chromatographic methods for the determination of a new carbapenem antibiotic, L-749345, in human plasma and urine. J Chromatogr B. 1998;720:99-106.
13. Musson DG, Majumdar A, Holland S, et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother. 2004;48:521-524.
14. Musson DG, Birk KL, Kitchen CJ, et al. Assay methodology for the quantitation of unbound ertapenem antibiotic in human plasma. J Chromatogr B. 2003;783:1-9.
15. Ji Z, Quan H, Ng J, Stepanavage M. Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials. 1997;18:204-221.
16. ROCEPHIN (ceftriaxone sodium) [US package insert]. In: Physicians' Desk Reference, 54th ed. Montvale, NJ: PDR Thomson; 2000.
17. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53(suppl 2):ii23-ii28.